Hu Xiao, Tan Jie, Luan Rumei, Ding Dongyan, Yue Ming, Yang Junling, Xue Qianfei
Department of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, China.
Shandong First Medical University Affiliated Provincial Hospital, Jinan, Shandong, China.
Front Med (Lausanne). 2025 Jul 9;12:1583843. doi: 10.3389/fmed.2025.1583843. eCollection 2025.
Lung cancer is among the malignancies most vulnerable to coronavirus disease 2019 (COVID-19). Eosinophils have anti-tumor and antiviral effects. Since November 2021, the omicron variant of COVID-19 has become a topic of concern; however, the impact of eosinophils on the severity and outcomes of patients with lung cancer with omicron remains uncertain. This study aimed to utilize eosinophils to predict patient outcomes and guide the prevention and monitoring of omicron.
This study performed an analysis of 284 patients with lung cancer who were hospitalized in the second hospital of Jilin University, of whom 83 patients were confirmed to have omicron infection. Depending on the eosinophil counts, patients were divided into two groups: low and high eosinophil counts. The relationship between eosinophil counts and severity and outcomes was then analyzed.
We found that omicron, especially severe-to-critical omicron, decreased survival in patients with lung cancer. Patients with omicron had a lower eosinophil count. Patients with eosinopenia (< 0.015 × 10/L) were more likely to have an eastern cooperative oncology group performance status ≥ 2; be undergoing anti-cancer treatment; have comorbidities; and exhibit lower disease control rates, reduced 30-day survival, and shorter overall survival (median 75 days vs. not reached). Multivariate regression analysis revealed that the eosinophil count was an independent predictor of disease severity and survival in patients with lung cancer with omicron.
Eosinopenia correlates with poor outcomes in patients with lung cancer with omicron, and the eosinophil count is an independent indicator for predicting the severity and outcomes in these patients.
肺癌是对2019冠状病毒病（COVID-19）最易感的恶性肿瘤之一。嗜酸性粒细胞具有抗肿瘤和抗病毒作用。自2021年11月以来，COVID-19的奥密克戎变异株成为关注焦点；然而，嗜酸性粒细胞对感染奥密克戎的肺癌患者的严重程度和预后的影响仍不确定。本研究旨在利用嗜酸性粒细胞预测患者预后，并指导奥密克戎的预防和监测。
本研究对吉林大学第二医院收治的284例肺癌患者进行分析，其中83例确诊感染奥密克戎。根据嗜酸性粒细胞计数，将患者分为两组：嗜酸性粒细胞计数低和高。然后分析嗜酸性粒细胞计数与严重程度和预后之间的关系。
我们发现，奥密克戎，尤其是重症至危重症奥密克戎，降低了肺癌患者的生存率。感染奥密克戎的患者嗜酸性粒细胞计数较低。嗜酸性粒细胞减少（<0.015×10⁹/L）的患者更有可能东部肿瘤协作组体能状态≥2；正在接受抗癌治疗；有合并症；并且疾病控制率较低、30天生存率降低和总生存期较短（中位生存期75天对未达到）。多因素回归分析显示，嗜酸性粒细胞计数是感染奥密克戎的肺癌患者疾病严重程度和生存的独立预测因素。
嗜酸性粒细胞减少与感染奥密克戎的肺癌患者的不良预后相关，嗜酸性粒细胞计数是预测这些患者严重程度和预后的独立指标。
